Mumps
📧 Sign up to get email alerts when something new happens for Mumps.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-08-13Clinical Trial Update: ProQuad® Intramuscular vs Subcutaneous [Phase 3]
Phase 3 trial comparing ProQuad intramuscular vs subcutaneous administration in measles/mumps rubella/varicella indications; results posted …
-
CLINICAL_TRIALS trial_result · 2018-07-03Clinical Trial Update: Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age [Phase 3]
A Phase 3 trial comparing GSK's MMR vaccine to Merck's MMR vaccine in healthy children 12 to 15 months old; results have been posted.
-
CLINICAL_TRIALS trial_result · 2018-06-28Clinical Trial Update: Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age [Phase 3]
A Phase 3 consistency study comparing GSK's MMR vaccine (Priorix) with Merck's M-M-R II in children 12 to 15 months, assessing immunogenicit…
-
CLINICAL_TRIALS trial_result · 2018-03-19Clinical Trial Update: Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) [Phase 3]
Phase 3 immunogenicity and safety study assessing concomitant administration of ProQuad and Infanrix Hexa has been completed and results pos…
-
CLINICAL_TRIALS trial_result · 2018-03-14Clinical Trial Update: Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children [Phase 4]
A Phase 4 trial assessing the safety and immunogenicity of the Measles-Mumps-Rubella vaccine delivered by a needle-free DSJI device compared…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-01-30Clinical Trial Update: Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) [Phase 3]
A Phase 3 comparative study evaluating immunogenicity and safety of a two-dose Regimen of ProQuad manufactured with rHA (V221-038) for measl…
-
CLINICAL_TRIALS trial_result · 2017-10-26Clinical Trial Update: Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants [Phase 3]
A Phase 3 trial completed to evaluate the safety and immunogenicity of a live attenuated mumps vaccine in healthy infants.
-
CLINICAL_TRIALS trial_result · 2017-10-17Clinical Trial Update: Safety Study of ProQuad® rHA in Infants (V221-037) [Phase 3]
Phase 3 safety study of ProQuad rHA in infants completed; results posted.
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds [Phase 2]
Phase 2 immunogenicity and safety study of GSK's 208136 vaccine formulated with new seed strains for measles and rubella; results posted aft…
-
CLINICAL_TRIALS trial_result · 2017-09-25Clinical Trial Update: Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM [Phase 3]
Phase 3 trial comparing GSK's MMRV vaccine to Priorix; the study is completed and results were posted on 2017-09-25.
-
CLINICAL_TRIALS trial_result · 2017-09-13Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age [Phase 3]
A Phase 3 clinical trial evaluating the immunogenicity and safety of GSK's combined MMR vaccine in children aged four to six years has compl…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine
An observational trial completed to assess the effectiveness of a one-dose mumps-containing vaccine in protecting children from mumps.
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine [Phase 4]
A Phase 4 trial sponsored by the Centers for Disease Control and Prevention, China, evaluated the immunization schedule for Beijing Tiantan …
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 [Phase 3]
Phase 3 immunogenicity and safety study of GlaxoSmithKline's combined measles-mumps-rubella-varicella vaccine has completed, with results po…
-
CLINICAL_TRIALS trial_result · 2017-04-10Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older [Phase 3]
Phase 3 trial evaluating the immunogenicity and safety of GlaxoSmithKline's combined measles-mumps-rubella vaccine in volunteers aged seven …
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) [Phase 2]
Phase 2 trial results assessing the safety, tolerability, and immunogenicity of an investigational recombinant human albumin (rHA)–based vac…
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Safety Study of a Refrigerator-stable Formulation of VARIVAX® [Phase 4]
The document reports the completion of a Phase 4 safety study of a refrigerator-stable formulation of VARIVAX (varicella vaccine) sponsored …
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of PriorixTetra when co-administered with a conjugated MenC vaccine in healthy children; …
-
CLINICAL_TRIALS trial_result · 2016-10-07Clinical Trial Update: Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ [Phase 2]
Phase 2 study assessing immunogenicity and safety of a combined Measles-Mumps-Rubella-Varicella vaccine (MeMuRu-OKA) compared with Priorix (…
-
CLINICAL_TRIALS trial_result · 2016-10-07Clinical Trial Update: Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ [Phase 2]
Phase 2 trial evaluating the immunogenicity and safety of the MeMuRu-OKA measles-mumps-rubella-varicella vaccine compared with Priorix given…
-
CLINICAL_TRIALS trial_result · 2016-09-26Clinical Trial Update: Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Phase 3]
Phase 3 trial evaluating the immunogenicity and safety of a combined measles, mumps, rubella, and varicella vaccine. The study has completed…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Phase 3]
A Phase 3 trial assessed the immunogenicity and safety of a combined measles, mumps, rubella and varicella vaccine (MMRV) developed by Glaxo…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases [Phase 4]
This Phase 4 trial update reports on the immunogenicity and safety of a combined measles, mumps, rubella, and varicella vaccine developed by…
-
CLINICAL_TRIALS trial_result · 2016-09-20Clinical Trial Update: Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. [Phase 4]
Phase 4 trial update evaluating GSK's MMR vaccine Priorix in healthy children aged 12 to 18 months in Singapore.
-
CLINICAL_TRIALS trial_result · 2016-09-15Clinical Trial Update: Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine [Phase 3]
This document reports long-term immunogenicity and safety results from a Phase 3 trial of the MMRV vaccine, evaluating durability of immune …